Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News Anthem Biosciences (NSE: ANTHEM) Q2 FY26 results: Can strong CRDMO tailwinds keep driving profitability? Anthem Biosciences Q2 FY26 results reveal strong CRDMO-led growth and 44.5% EBITDA margins. Find out what’s driving investor sentiment and what’s next. byVenkateshNovember 9, 2025